Navigation Links
Arthritis patients taking newer treatments do not have an overall increased cancer risk
Date:5/27/2011

Only three percent (n=181) of patients in the study cohort receiving anti-tumour necrosis factor agents (anti-TNFs) for treatment of their arthritis developed a first cancer within nine years and overall risk was not dependent on the type of arthritis.

The nine year follow-up study conducted at Gentofte University Hospital, Denmark demonstrated that relative risk ((RR)=1.03 (95%confidence interval 0.82-1.30)) was not increased in patients treated with anti-TNFs compared to patients who had never taken anti-TNFs during 23,965 person-years follow-up. Overall cancer risk was not dependent on the type of arthritis including rheumatoid arthritis (RA) (n=3,496) (RR=1.05, 95% CI 0.82-1.34), psoriatic arthritis (PsA) (n=670) (RR=1.98, 95% CI 0.24-16.18) or other arthritis (n=499) (RR=0.79 95% CI 0.08-8.33).

"Some studies have suggested that taking anti-TNFs may increase an individual's risk of cancer however this study provides long term evidence that an overall risk of cancer is not associated with this group of treatments", said Dr. PhD, Lene Dreyer from the Department of Rheumatology at Gentofte University Hospital. "TNF is a small signalling molecule called a cytokine and is able to inhibit the development of tumours by interfering with signalling pathways. Therefore drugs targeting TNF can influence the development of tumours, although the extent of this impact remains unclear."

The study was based on the national Danish DANBIO registry which was initiated in the year 2000 to monitor treatment with biologic medicines in Denmark and includes patients with RA, PsA and ankylosing spondylitis. A national cohort of 13,699 patients was identified and of these, 5,598 (41 percent) had started anti-TNF treatment. The data from the DANBIO database was linked with the Danish Cancer Registry and analysed.

Incidence of cancer among patients ever treated with anti-TNF agents was compared to that of patients not treated, by evaluating relative
'/>"/>

Contact: Rory Berrie
rory.berrie@cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related biology news :

1. Geisinger research: Antimalarial drug prevents diabetes in arthritis patients
2. New therapeutic target identified for rheumatoid arthritis
3. Anakinra for rheumatoid arthritis: A modest benefit with some risk
4. Gene therapy demonstrates benefit in patients with rheumatoid arthritis
5. Inhibiting proteins may prevent cartilage breakdown in arthritis patients
6. Bad mix of bacterial remnants and genetics leads to arthritis
7. Researchers identify new risk factor gene for rheumatoid arthritis
8. New trigger for chronic inflammation in rheumatoid arthritis discovered
9. Gene expression findings a step toward better classification and treatment of juvenile arthritis
10. Arthritis Foundation of India Trust named winner of 2009 IOF Linda Edwards Memorial Award
11. BUSPH study links rheumatoid arthritis to vitamin D deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... the nasty habit of getting tangled and forming knots. ... learn how to disentangle them (e.g. useful for gene ... for Advanced Studies (SISSA) in Trieste and his team ... these knots and their dynamics. In their latest paper, ... Micheletti together with Marco Di Stefano, first author and ...
(Date:7/23/2014)... German . ... some of which might be very different from ours. ... produced by sunlight in the atmosphere to calibrate their ... for Ornithology in Seewiesen, Germany, and Queen,s University Belfast ... active mammal, the greater mouse-eared bat, has the capability ...
(Date:7/23/2014)... no cure exists for Alzheimer,s disease, the devastating ... But scientists are now reporting new progress on ... treatment, that shows promise as a potential oral ... Journal of Medicinal Chemistry . , Carlo ... in a healthy brain, the protein known as ...
Breaking Biology News(10 mins):Bats use the evening sky's polarization pattern for orientation 2
... Pop culture heedlessly and wrongly lumps these ... because the creatures flew, they were birdlike in many ways, ... Now comes what is believed to be ... into flight required pterosaurs to use four limbs: two were ...
... of the American Dietetic Association features research studies focusing ... sack lunches may not always meet the nutritional needs of ... diets of young adults. Packing a Lunch for ... 13 million children in the United States eat three or ...
... CAA lack of technology needed to explore and monitor ... critical bottleneck for Earth scientists, conservationists, and forest managers. ... composition and function of these forests and how they ... other threats. Gregory Asner and his team at the ...
Cached Biology News:Four, three, two, one . . . pterosaurs have lift off 2News from the January 2009 Journal of the American Dietetic Association 2New rainforest mapping technology gets huge support 2
(Date:7/23/2014)... ANTONIO , 23 de julio de 2014 ... (ADBI o la Compañía) ha anunciado hoy una ... Akron (ABIA o el Instituto), para ... ADBI, un dispositivo de terapia de señal bioeléctrica ... El Instituto, que tiene una importante ...
(Date:7/23/2014)... July 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... producing sustainable chemicals, today announced that the underwriters of ... option to purchase an additional 420,000 shares of ... $12.00 per share, less underwriting discounts and commissions, ... offering of 2,800,000 shares of common stock, bringing ...
(Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
(Date:7/23/2014)... 23, 2014 a2z Inc. announces that ... App, AACC Pathfinder, in its 2014 Annual Meeting ... meeting is planned for July 29-31, 2014 in Chicago, ... be to connect with global leaders in clinical chemistry, ... other areas of breaking science in laboratory medicine. , ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... ,The dial-in code is: 3684539 To view ... Upcoming Financial Date: February 2012 ... 2011 This press release contains statements about ... of these statements cannot be guaranteed as they are ...
... Oncology announces completion of a phase I Small Business ... Cancer Institute (NCI).  The SBIR grant project ... (JIT) to enroll cancer patients into clinical trials. ... with qualifying diagnoses across many research practices. Patients who ...
... Oct. 20, 2011 Med track is pleased ... 2011. Attendees of the show will be the first ... the newly designed platform. With deeply integrated datasets and ... professionals in business development, competitive intelligence and sales and ...
Cached Biology Technology:Nine-Month Figures for 2011: Dynamic, Profitable Growth at Sartorius 2Pharmatech Oncology Announces Completion of SBIR Grant Research 2Be One of the First to Experience the New Medtrack Platform at BIO®-Europe 2011 2
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
oligophrenin-1 (H-100)...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
Biology Products: